JMP Securities analyst Jonathan Wolleben reiterated a Buy rating on Madrigal Pharmaceuticals (MDGL – Research Report) today and set a price target of $180.00. The company’s shares opened today at $66.86.
According to TipRanks, Wolleben is a 2-star analyst with an average return of 0.0% and a 38.89% success rate. Wolleben covers the Healthcare sector, focusing on stocks such as Altimmune, Madrigal Pharmaceuticals, and Intercept Pharma.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Madrigal Pharmaceuticals with a $141.67 average price target.
See today’s best-performing stocks on TipRanks >>
Based on Madrigal Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $70.73 million. In comparison, last year the company had a GAAP net loss of $61.65 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
Read More on MDGL:
